Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis Konstantinos.

Slides:

Advertisements

Similar presentations

Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta- analysis Eline J.C.A. Kamp, John S. Kane, Alexander C. Ford Clinical Gastroenterology.

Advertisements

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire,

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis Konstantinos.

Volume 134, Issue 7, Pages (June 2008)

Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease David Drobne, Peter Bossuyt,

Abnormal Liver Tests and Fatty Liver on Ultrasound

Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease David Drobne, Peter Bossuyt,

Ashwin N. Ananthakrishnan, Millie D. Long, Christopher F

Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis Jeffrey Hyams, Lakshmi Damaraju, Marion Blank,

Volume 138, Issue 2, Pages (February 2010)

Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis Alexander C. Ford, Khurram J. Khan, William.

Issue Highlights Clinical Gastroenterology and Hepatology

Pichamol Jirapinyo, Christopher C. Thompson

Laura Rosenberg, Kavinderjit S

Low-Dose Maintenance Therapy With Infliximab Prevents Postsurgical Recurrence of Crohn's Disease Dario Sorrentino, Alberto Paviotti, Giovanni Terrosu,

Walter Reinisch, Andrew R. Reinink, Peter D.R. Higgins

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire,

Immune Reconstitution Inflammatory Syndrome of the Small Bowel in a Human Immunodeficiency Virus–Negative Patient Severin Daum, Christoph Loddenkemper,

Fernando Velayos, Uma Mahadevan

Right Upper Quadrant Pain and a Normal Abdominal Ultrasound

Trends in Overall and Cause-Specific Mortality Among Patients With Inflammatory Bowel Disease From 1982 to 2010 Tine Jess, Morten Frisch, Jacob Simonsen

Pushing the Pedal to the Metal: Should We Accelerate Infliximab Therapy for Patients With Severe Ulcerative Colitis? Hans H. Herfarth, MD, PhD Clinical.

Long-term outcome after infliximab for refractory ulcerative colitis

Liver Cirrhosis Is Associated With Venous Thromboembolism Among Hospitalized Patients in a Nationwide US Study Harry Wu, Geoffrey C. Nguyen Clinical.

Endoscopic and Clinical Variables That Predict Sustained Remission in Children With Ulcerative Colitis Treated With Infliximab Dan Turner, Anne M. Griffiths,

Mucosal Healing in Patients With Celiac Disease and Outcomes of Pregnancy: A Nationwide Population-Based Study Benjamin Lebwohl, Olof Stephansson, Peter.

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease Matthias Jürgens, Jestinah M. Mahachie.

Volume 134, Issue 7, Pages (June 2008)

Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies Tine Jess, Christine Rungoe, Laurent.

Amnon Sonnenberg, MD, MSc, Brent Y. Lee, MD

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease Elana A. Maser, Renata Villela,

Volume 148, Issue 7, Pages e3 (June 2015)

Endoscopic Therapy for Barrett's Esophagus

A Randomized Controlled Trial of Enemas in Combination With Oral Laxative Therapy for Children With Chronic Constipation Marloes E.J. Bongers, Maartje.

Leon P. McLean, Jonathan S. Chun, Raymond K. Cross

Obstructive Jaundice Caused by Intraductal Hepatocellular Carcinoma

Issue Highlights Clinical Gastroenterology and Hepatology

Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis John Gubatan, Shuji Mitsuhashi, Talia Zenlea,

Abnormal Liver Tests and Fatty Liver on Ultrasound

Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis

Protein-Losing Enteropathy in Crohn’s Disease

Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis Laurent Peyrin-Biroulet, Gert Van Assche, Alessandro.

Volume 147, Issue 6, Pages e5 (December 2014)

New Models of Gastroenterology Practice

Reenu Malhotra, Kevin Turner, Amnon Sonnenberg, Robert M. Genta

Stephen J. Rulyak, David A. Lieberman, Edward H. Wagner, Margaret T

Efficacy of Esophageal Impedance/pH Monitoring in Patients With Refractory Gastroesophageal Reflux Disease, on and off Therapy Jason M. Pritchett, Muhammad.

David H. Bruining, William J. Sandborn

Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging Konstantinos Karmiris, Didier.

Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis Shailja C.

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases Xavier Roblin, Hubert Marotte, Melanie.

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy Filip Baert, David Drobne, Ann Gils,

Effects of Different Coping Strategies on Physical and Mental Health of Patients With Irritable Bowel Syndrome Lilian Dindo, PhD Clinical Gastroenterology.

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity Severine Vermeire, Stefan Schreiber,

Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis David N. Moskovitz, Gert Van Assche,

James Allison, Lisa J. Herrinton, Liyan Liu, Jenny Yu, James Lowder

Walter Reinisch, Jean-Frederic Colombel, William J

A 27-Year-Old Woman With Constipation: Diagnosis and Treatment

Issue Highlights Clinical Gastroenterology and Hepatology

Issue Highlights Clinical Gastroenterology and Hepatology

Black and White Liver Clinical Gastroenterology and Hepatology

Medical Therapy for Refractory Pediatric Crohn’s Disease

Issue Highlights Clinical Gastroenterology and Hepatology

Thomas G. Cotter, John S. Van Arnam, John A. Schaffner

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases Konstantinos Papamichael, Adam S. Cheifetz,

Richard A. Hansen, Gerald Gartlehner, Gregory E. Powell, Robert S

Volume 157, Issue 4, Pages e6 (October 2019)

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis Jean-Frédéric Colombel,

An Unusual Skin Manifestation in a Patient With Ulcerative Colitis

Presentation transcript:

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis Konstantinos Papamichael, Thomas Van Stappen, Niels Vande Casteele, Ann Gils, Thomas Billiet, Sophie Tops, Karolien Claes, Gert Van Assche, Paul Rutgeerts, Severine Vermeire, Marc Ferrante Clinical Gastroenterology and Hepatology Volume 14, Issue 4, Pages 543-549 (April 2016) DOI: 10.1016/j.cgh.2015.11.014 Copyright © 2016 AGA Institute Terms and Conditions

Figure 1 Flowchart of the study population. Clinical Gastroenterology and Hepatology 2016 14, 543-549DOI: (10.1016/j.cgh.2015.11.014) Copyright © 2016 AGA Institute Terms and Conditions

Figure 2 ROC analysis for infliximab serum concentrations at week 2 (A), week 6 (B), and week 14 (C) stratifying patients with and without STMH. Clinical Gastroenterology and Hepatology 2016 14, 543-549DOI: (10.1016/j.cgh.2015.11.014) Copyright © 2016 AGA Institute Terms and Conditions

Figure 3 Distribution of serum infliximab concentrations during induction therapy on the basis of STMH. Gray boxes represent infliximab serum concentrations of patients with STMH, and white boxes represent infliximab serum concentrations of patients without STMH. Box plots (5%–95%) show the median (solid line within box), IQR (upper and lower box boundaries), standard deviation (whiskers), and outliers (black dot) (A). Rates of STMH by infliximab serum concentration quartiles at weeks 2, 6, and 14 (P values indicate comparison across quartiles, χ2 test (linear-by-linear association) (B). w, week. Clinical Gastroenterology and Hepatology 2016 14, 543-549DOI: (10.1016/j.cgh.2015.11.014) Copyright © 2016 AGA Institute Terms and Conditions

Figure 4 Total infliximab exposure of patients with and without STMH. Average infliximab concentrations for UC patients with or without STMH are represented by (■) and (•), respectively, and 95% CIs are represented by the red and black dotted lines, respectively. Clinical Gastroenterology and Hepatology 2016 14, 543-549DOI: (10.1016/j.cgh.2015.11.014) Copyright © 2016 AGA Institute Terms and Conditions